Boehringer Ingelheim and The University of Texas MD Anderson
Cancer Center announced a new multi-year partnership to conduct collaborative research to rapidly advance therapies for various types of cancers, including gastrointestinal and lung cancers.
ENPNewswire-August 13, 2019--Boehringer Ingelheim and MD Anderson
form unique Virtual Research and Development Center to rapidly advance new cancer therapies
M2 PHARMA-August 13, 2019-Boehringer Ingelheim and MD Anderson
Form Virtual Research and Development Centre to Rapidly Advance New Cancer Therapies
Adaptimmune Therapeutics has initiated a radiation sub-study of its ADP-A2M4 trial in collaboration with the University of Texas MD Anderson
Cancer Center in Houston, TX.
Pocket Radiation Oncology: The MD Anderson
Cancer Center Handbook of Radiation Oncology
The partnership is the product of work between leaders from both organizations, but one of the strongest voices in creating the arrangement was that of MD Anderson
President Peter W.T.
The event was hosted by Hikma Pharmaceuticals PLC (Hikma, Group) (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (rated Ba1 Moody's / BB+ S&P, both stable), the multinational generic pharmaceutical company, in collaboration with the University of Texas MD Anderson
Cancer Center - Department of Leukemia.
and The University of Texas MD Anderson
Cancer Center have entered into a three-year agreement that will enable clinical evaluation for safety and efficacy of three Cyclacel medicines in patients with hematological malignancies, several advanced leukemias.Berkeley Heights-based Cyclacel Pharmaceuticals Inc.
M2 EQUITYBITES-May 31, 2018-Ipsen signs global licensing and joint development agreement with The University of Texas MD Anderson
Following the ribbon-cutting ceremony marking the consulate's inauguration, the officials spoke at a reception hosted in collaboration with the University of Texas MD Anderson
Cancer Centre, to celebrate the consulate's opening and highlight the partnership between the UAE and Houston.
Presenters from MD Anderson
reflected on the past decade and shared their personal experiences along with technical and clinical overviews of proton therapy at MD Anderson
The Rockefeller Group expects to break ground this summer on the facility that it is developing on behalf of a partnership between Summit Medical Group and the University of Texas MD Anderson
Cancer Center, which recently signed a long-term lease at the property.